Critical Contrast: Threshold Pharmaceuticals (MTEM) versus The Competition
Threshold Pharmaceuticals (NASDAQ: MTEM) is one of 295 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Threshold Pharmaceuticals to similar businesses based on the strength of its analyst recommendations, risk, valuation, profitability, institutional ownership, dividends and earnings.
Risk and Volatility
Threshold Pharmaceuticals has a beta of 3.34, indicating that its share price is 234% more volatile than the S&P 500. Comparatively, Threshold Pharmaceuticals’ competitors have a beta of 6.66, indicating that their average share price is 566% more volatile than the S&P 500.
This is a breakdown of recent ratings and price targets for Threshold Pharmaceuticals and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Threshold Pharmaceuticals Competitors||761||3027||11175||227||2.72|
Threshold Pharmaceuticals currently has a consensus price target of $5.20, indicating a potential downside of 39.53%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 37.69%. Given Threshold Pharmaceuticals’ competitors stronger consensus rating and higher probable upside, analysts plainly believe Threshold Pharmaceuticals has less favorable growth aspects than its competitors.
Earnings and Valuation
This table compares Threshold Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Threshold Pharmaceuticals Competitors||$260.16 million||$66.28 million||-6.61|
Threshold Pharmaceuticals’ competitors have higher revenue and earnings than Threshold Pharmaceuticals. Threshold Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
50.5% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 13.0% of Threshold Pharmaceuticals shares are held by company insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Threshold Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Threshold Pharmaceuticals Competitors||-5,511.45%||-449.45%||-42.34%|
Threshold Pharmaceuticals competitors beat Threshold Pharmaceuticals on 9 of the 11 factors compared.
Threshold Pharmaceuticals Company Profile
Molecular Templates, Inc., formerly Threshold Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. Evofosfamide is designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not in healthy tissues. Tarloxotinib is under investigation in two Phase II proof-of-concept trials: one for the treatment of patients with mutant EGFR-positive, T790M-negative advanced NSCLC progressing on an EGFR TKI, and the other for patients with recurrent or metastatic squamous cell carcinomas of the head and neck. [18F]-HX4 is an investigational Positron Emission Tomography imaging agent for hypoxia to identify.
Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.